{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-030473","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.942032+00:00","generated_at":"2026-06-04T02:28:02.427018+00:00","sec_items":["3.03","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity Therapeutics approves 1-for-20 reverse stock split effective April 9, 2024","bullets":["Stockholders approved 1-for-20 reverse stock split at April 1 special meeting; ratio set by Board.","Reverse split effective April 9, 2024 at 9:30 a.m. ET; trading symbol ALLR unchanged; new CUSIP 016744401.","No fractional shares issued; any fractional rounded up to next whole number. Authorized shares unchanged at 750M.","Amendment to 2021 Equity Incentive Plan passed, adding 1,000,000 authorized shares.","Adjournment proposal also passed but not needed as reverse split proposal already approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-030473","json":"https://secwatch.observer/filing/0001213900-24-030473.json","markdown":"https://secwatch.observer/filing/0001213900-24-030473.md","text":"https://secwatch.observer/filing/0001213900-24-030473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/ea0203322-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:28:02.427018+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"80d76150929d8fe192d5c7831e5fefb5f66450c2","claim":"Allarity Therapeutics, Inc.: Filed Fifth Certificate of Amendment to effect a 1-for-20 reverse stock split of common stock (effective 2024-04-09).","evidence_excerpt":"On April 4, 2024, Allarity Therapeutics, Inc., a Delaware corporation (the “Company”) filed a Fifth Certificate of Amendment to Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), effective as of 9:30 a.m. (Eastern Time) on April 9, 2024","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2024-04-09"}],"fact_type":"governance_change"},{"claim_id":"683db28d2f444998356e848a72f5539e097e5c01","claim":"Allarity Therapeutics, Inc. shareholders approved Approve adjournment of special meeting to solicit additional proxies in favor of Reverse Stock Split Proposal.","evidence_excerpt":"Proposal 3 : To approve the adjournment of the meeting, if necessary or advisable, to solicit additional proxies in favor of the Reverse Stock Split Proposal (the “Adjournment Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 4,598,095 1,130,018 4,143 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"b7754631a2b3f21b343d636a6ba2a9a0c79f1e59","claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to 2021 Equity Incentive Plan to increase authorized shares by 1,000,000.","evidence_excerpt":"Proposal 1 : To approve an amendment to the Allarity Therapeutics, Inc. 2021 Equity Incentive Plan, a copy of such amended and restated plan is included as Appendix A to the Proxy Statement (the “2021 Plan”), to increase the aggregate number of shares of Common Stock authorized for issuance by 1,000,000 shares (the “Amendment to the 2021 Plan Proposal”). Votes For Votes Against Abstentions Broker Non-Votes 3,898,165 294,784 1,917 1,537,390","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"},{"claim_id":"d3e73530098c95bb849d35d64e05a8c778a88972","claim":"Allarity Therapeutics, Inc. shareholders approved Approve amendment to Certificate of Incorporation to effect reverse stock split at ratio between 1:5 and 1:20.","evidence_excerpt":"Proposal 2 : To approve an amendment to the Allarity Therapeutics, Inc. Certificate of Incorporation, as amended (the “Charter Amendment”), in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding Common Stock, par value $0.0001 per share, at a ratio between 1-for-5 and 1-for-20 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Votes For Votes Against Abstentions Broker Non-Votes 4,619,400 1,095,954 16,902 -","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024030473/0001213900-24-030473-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}